Now you have the first and only FLT3 inhibitor to specifically target the FLT3-ITD mutation—one of the most aggressive threats in AML.2-7

paper and pen gear icon

Enroll today to prescribe VANFLYTA with a one-time training for the VANFLYTA Risk Evaluation and Mitigation Strategy (REMS).

person gear icon
Resources and Support

Here you’ll find the information, tools, and forms you need to start treating with VANFLYTA.

VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)–positive as detected by an FDA-approved test.3

Limitations of Use: VANFLYTA is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival with VANFLYTA in this setting has not been demonstrated.

*Studied comparing 5-year survival rates of patients with TKD mutations (53% OS) vs patients with ITD mutations (15% OS).1,2
AML=acute myeloid leukemia; FLT3=FMS (feline McDonough sarcoma)–like tyrosine kinase 3; ITD=internal tandem duplication; TKD=tyrosine kinase domain.

Request a Contact

Complete the form below to request a VANFLYTA sales representative.

*Required fields.

Click here to find your NPI number.

By clicking GET STARTED, you attest that you are a licensed healthcare professional.

The privacy and security of your personal information is important to Daiichi Sankyo, Inc. The information that you provide to us will be shared with and among our business partners for purposes related to Daiichi Sankyo, Inc, products, programs, services, and market research. Your personal information will not be used by any of our business partners for their own marketing purposes. By providing your information above, you agree that Daiichi Sankyo, Inc, and our business partners may send you information about our products, programs, and services from time to time. You will be able to cancel your participation at any time by using the unsubscribe link from emails. For further information about Daiichi Sankyo, Inc, privacy practices, please review our Terms and Conditions and Privacy Policy.

Please note: At any time, if you decide you no longer wish to receive information by email, you will be able to unsubscribe.

VANFLYTA Resources and Support

Tools and resources for you and your patients including clinical data, dosing, and patient access.

Clinical Resources

clinical brochure icon

Clinical Brochure

Read the full VANFLYTA data, including efficacy and safety, in this robust clinical guide.

dosing guide icon

Dosing Guide

Learn about the VANFLYTA dosing and administration.


Office Support

product access icon

Product Access

Learn about financial assistance programs for your patients, download coding and claim resources and view a list of network specialty distributors and specialty pharmacies.

reimbursement specialist icon


Find support with HIPAA-certified, field-based specialists who can help answer your access and reimbursement questions.

Available Monday–Friday,*
8:00 AM–6:00 PM ET
*Excludes holidays.



To prescribe VANFLYTA, read more on how you can enroll in the VANFLYTA REMS.


Patient Resources

patient brochure icon

Patient Brochure

Supportive information for your eligible patients as they begin treatment with VANFLYTA.

patient support icon

Patient Support

See the available support programs to help patients access VANFLYTA.